Marks Gilbert Lynn
SEC insider (Form 3/4/5 filer). CIK 0001916940. Director at AN2 Therapeutics, Inc. (ANTX). 16 reported Form 4/5 transactions since Sep 2024; latest on Oct 12, 2026. Located in MENLO PARK, CA.
Companies Marks Gilbert Lynn has filed insider reports for
- AN2 Therapeutics, Inc. (ANTX): Director
Marks Gilbert Lynn
CIK: 0001916940
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
AN2 Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (16 total)
- Oct 12, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirect2.3K shares- - Jul 10, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirect2.8K shares- - Apr 10, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirect3.8K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
DispositionDirectStock Option (right to buy)
10.4K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirectStock Option (right to buy)
10.7K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
DispositionDirectStock Option (right to buy)
23.7K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirectStock Option (right to buy)
23.7K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirectStock Option (right to buy)
10.4K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
DispositionDirectStock Option (right to buy)
10.7K shares- - Feb 20, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
20.4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 12, 2026 | ANTX AN2 Therapeutics, Inc. | Award | 2,283 | - | $0 | Direct |
| Jul 10, 2026 | ANTX AN2 Therapeutics, Inc. | Award | 2,789 | - | $0 | Direct |
| Apr 10, 2026 | ANTX AN2 Therapeutics, Inc. | Award | 3,775 | - | $0 | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition Stock Option (right to buy) | 10,362 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award Stock Option (right to buy) | 10,665 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition Stock Option (right to buy) | 23,742 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award Stock Option (right to buy) | 23,742 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award Stock Option (right to buy) | 10,362 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition Stock Option (right to buy) | 10,665 | - | - | Direct |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc. | Award Stock Option (Right to Buy) | 20,400 | - | - | Direct |
1-10 of 16 transactions